CTI BioPharma Corp.Find Ratings Reports
CTI BIOPHARMA CORP's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. CTI BIOPHARMA CORP has average liquidity. Currently, the Quick Ratio is 1.38 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 176.85% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||4.43||0.96|
|Net Income ($mil)||-29.18||-32.59|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||61.61||46.36|
|Total Assets ($mil)||76.49||63.13|
|Total Debt ($mil)||21.1||51.65|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||-642.23||-3289.21|
|Return on Assets||-93.18||-214.39|
|Return on Equity||-416.26||0.0|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||28.25||19.18|
|Div / share||0.0||0.0|
|Book value / share||0.63||-1.21|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||785982.0||648686.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.49 indicates a significant premium versus the S&P 500 average of 2.94 and a significant discount versus the industry average of 11.06. The price-to-sales ratio is above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CTI BIOPHARMA CORP proves to trade at a discount to investment alternatives within the industry.
|CTIC NM||Peers 37.42||CTIC NM||Peers 19.90|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CTIC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CTIC's P/CF is negative making the measure meaningless.
|CTIC NA||Peers 41.46||CTIC NA||Peers 0.53|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CTIC 7.49||Peers 11.06||CTIC 64.20||Peers 125.26|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CTIC is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CTIC is expected to significantly trail its peers on the basis of its earnings growth rate.
|CTIC 2.25||Peers 146.34||CTIC 163.90||Peers 626.06|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CTIC is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CTIC significantly trails its peers on the basis of sales growth